813例儿童范可尼贫血患者造血干细胞移植结局分析
该回顾性多中心研究分析了2010至2018年间接受首次造血干细胞移植的813例范可尼贫血患儿,中位随访3.7年,5年总生存率83%、无事件生存率78%、无GVHD无复发生存率70%,匹配家庭供者与匹配无关供者总生存相当且优于其他供者类型。
要点
- 5年总生存率83%,无事件生存率78%,无GVHD无复发生存率70%。
- 匹配家庭供者与匹配无关供者总生存相当,优于错配供者及单倍体供者。
- 移植指征为AML/MDS、使用错配供者及单倍体供者独立预测较差总生存。
核心结论
- 这些数据提示,对于范可尼贫血合并再生障碍性贫血/骨髓衰竭的患者,应在较年轻时、有良好匹配供者的情况下提供造血干细胞移植。
研究设计与样本
- 回顾性多中心研究,纳入2010年至2018年间接受首次造血干细胞移植的813例范可尼贫血患儿,中位随访3.7年,移植时中位年龄8.8岁(IQR 6.5-18.1)。
主要发现
- 5年总生存率83%(95%CI 80-86),无事件生存率78%(95%CI 75-81),无GVHD无复发生存率70%(95%CI 67-74)。
- 总生存率在匹配家庭供者组(n=441,88%)与匹配无关供者组(n=162,86%)之间相当,且优于错配家庭供者或错配无关供者组(n=144,72%)及单倍体供者组(n=66,70%;P<.001)。
- 多因素分析中,移植指征为AML/MDS(对比AA/BMF)、使用错配家庭供者/错配无关供者和单倍体供者(对比匹配家庭供者)以及氟达拉滨-环磷酰胺(FluCy)联合其他预处理(对比FluCy)独立预测较差总生存;阿仑单抗对比抗胸腺细胞球蛋白与更好总生存相关。
- 年龄≥10岁与更差的无事件生存率和无GVHD无复发生存率相关。
- 原发性和继发性植入失败的累积发生率分别为2%和3%,3-4级急性GVHD和慢性GVHD的累积发生率分别为12%和8%,5年继发性恶性肿瘤累积发生率为2%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only established curative option for Fanconi anemia (FA)-associated bone marrow failure (BMF)/aplastic anemia (AA) and acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS). We performed a retrospective multicenter study on 813 children with FA undergoing first HSCT between 2010 and 2018. Median duration of follow-up was 3.7 years. Median age at transplant was 8.8 years (IQR, 6.5-18.1). Five-year overall survival (OS), event-free survival (EFS), and graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS) were 83% (95% confidence interval [CI], 80-86), 78% (95% CI, 75-81), and 70% (95% CI, 67-74), respectively. OS was comparable between matched family donor (MFD; n = 441, 88%) and matched unrelated donor (MUD; n = 162, 86%) and was superior to that of mismatched family donor (MMFD) or mismatched unrelated donor (MMUD; n = 144, 72%) and haploidentical donor (HID; n = 66, 70%; P < .001). In multivariable analysis, a transplant indication of AML/MDS (vs AA/BMF), use of MMFD/MMUD and HID (vs MFD), and fludarabine-cyclophosphamide (FluCy) plus other conditioning (vs FluCy) independently predicted inferior OS, whereas alemtuzumab vs antithymocyte globulin was associated with better OS. Age ≥10 years was associated with worse EFS and GRFS. Cumulative incidences (CINs) of primary and secondary graft failure were 2% and 3% respectively. CINs of grade 3 to 4 acute GVHD and chronic GVHD were 12% and 8% respectively. The 5-year CIN of secondary malignancy was 2%. These data suggest that HSCT should be offered to patients with FA with AA/BMF at a younger age in the presence of a well-matched donor.
引用
- Lum SH, Eikema DJ, Piepenbroek B, et al. Outcomes of hematopoietic stem cell transplantation in 813 pediatric patients with Fanconi anemia. Blood. 2024. PMID: 38968140. doi:10.1182/blood.2023022751
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。